Vision

• Affitech is building an international biopharmaceutical company focused on developing human therapeutic antibody drugs derived from the Company’s human antibody platform bringing new treatment options to improve patients’ lives.

R&D Strategy

• Rapid value creation through unique relationship with Russian pharmaceutical company and corresponding access to Russian and CIS markets
• Build portfolio of partnered and proprietary biopharmaceutical products
• Build competitive capabilities
• Industrialize CBASTM, extend library size and library technologies
• Remain at the forefront of Innovative Mab Technology
• Bispecific formats, enhanced mode of action